Welcome to Panacea Infarm
Opening Hours : Monday to Saturday - 8am to 9pm
Contact : +6 1385 9264 66
News
Apr
28

The cost of Merovir will be even lower for countries with a low standard of living

Panacea Infarm has announced a price reduction for Merovir for countries with a low standard of living (Russia, CIS, some European countries, South America, African countries).

Read more
Feb
18

Hepatitis B treatment is too expensive: Panacea Infarm is forced to reduce the price of Meravir

Hepatitis B is recognized as a global epidemic due to its high prevalence and a major risk of being affected by a virus. Until recently, the disease was considered incurable.

Read more
Jan
28

According to the clinical studies results the effectiveness of the drug FABI256 reaches 85%

Scientists got the clinical trials results of the drug FABI256 aimed to treat chronic viral hepatitis B and D.

Read more
Jan
27

The generic Meravir drug will safe Russia from hepatitis B

The Australian company Panacea Infarm is a major player in the biopharmaceutical market engaged in the development of various drugs. The company has announced its plans to transfer the right to manufacture generic of its drug no earlier than one year from now.

Read more
Dec
30

A new cure strategy for hepatitis B using the most effective drug Meravir

Hepatitis B is the only virus coping with the existing vaccine against it, still continuing to kill millions of people worldwide. Today Hepatitis B drugs represent a separate pharmaceutical market.

Read more
Dec
25

Attention and Excitement are growing: the release of the drug for hepatitis B is coming closer

 25.12. 2018

Hepatitis B incidence statistics are depressing, to put it mildly. According to the results of a large-scale study published in The Lancet Gastroenterology & Hepatology, only 1 out of 20 patients with the virus among the 300 million infected receives the required treatment.

Read more
Feb
25

The clinical trials of the hepatitis B drug FABI256 with the participation of people have started

Statistics show that more than 1 million people worldwide dies from different hepatitis B effects. According to Rospotrebnadzor (Federal Service for Consumer Rights Protection and Human Welfare in Russian Federation), in 2017 over 14,000 cases of chronic hepatitis B were registered in Russia, 1.3 thousand people suffers from an acute condition of this disease. All that the contemporary pharmaceutical market can offer such patients today is medicines suppressing the virus but not destroying it. 

Read more
Dec
05

The extensive clinical trials of a new hepatitis B drug involving human beings is launched

05.12.2014

The company Panacea Infarm continues to work on a clinical trial for patients suffering from chronic viral hepatitis B with the delta agent.

Read more
Aug
28

Panacea Infarm researches a new hepatitis B drug with the codename FABI256

25.11.2013

Hepatitis B is a worldwide public health problem. This potentially life-threatening infection affects a liver. The complications may result in the development of cirrhosis and cancer.

Read more